Daehan Nupharm Launches Enpiflu Premix, a Single-Dose Influenza Treatment
核心洞察
Daehan Nupharm (搜索) has launched Enpiflu Premix, a premixed peramivir hydrate injection, offering a single-dose intravenous treatment for influenza A (搜索) and B in adults and children.
Clinical trials across Korea, Japan, and Taiwan involving 1,091 adult patients demonstrated peramivir's effectiveness is comparable to oseltamivir in reducing symptom duration.
Enpiflu Premix's ready-to-use formulation enhances safety and efficiency by eliminating compounding, reducing preparation time, and minimizing contamination risks.
Daehan Nupharm (搜索) has announced the launch of Enpiflu Premix (peramivir hydrate) injection, a new premixed intravenous treatment for influenza A (搜索) and B. This single-dose formulation offers an alternative to traditional oseltamivir-based treatments, which require twice-daily administration for five days.
Single-Dose Efficacy and Convenience
Enpiflu Premix is approved by the Ministry of Food and Drug Safety for use in adults and children aged two years and older. Clinical trials involving 1,091 adult patients with influenza A (搜索) or B, conducted across 146 medical centers in Korea, Japan, and Taiwan, showed that a single dose of peramivir is as effective as oseltamivir in reducing the time to symptom improvement when administered within 48 hours of symptom onset. These findings suggest that Enpiflu Premix offers a comparable therapeutic benefit with a more convenient administration schedule.
Streamlined Administration and Reduced Risks
A key advantage of Enpiflu Premix is its ready-to-use infusion bag, which eliminates the need for compounding. According to Daehan Nupharm (搜索), this premixed formulation enhances efficiency and safety by reducing preparation time, cutting costs associated with diluents and syringes, and minimizing contamination risks during administration. This streamlined process could be particularly beneficial in busy clinical settings and may improve adherence to treatment protocols.
Market Growth and Future Outlook
The market for peramivir formulations has experienced substantial growth, increasing from 9.8 billion won ($7.38 million) in 2021 to 36.1 billion won in 2023. This surge is largely attributed to the increased incidence of influenza (搜索) since the onset of the COVID-19 pandemic. "We focused on rapid approval and launch to ensure stable supply and demand ahead of this year's flu season," said a representative from Daehan Nupharm (搜索), highlighting the company's commitment to providing convenient and effective influenza treatments. The company aims to continue innovating in this space by streamlining operations at medical sites, eliminating the mixing process, and increasing treatment convenience for patients.